triphenylethylene

09/01/2014 - "Triphenylethylene (TPE)-like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. "
01/01/2012 - "The aim of this work was to develop a novel (99m)Tc-labelled derivative based on triphenylethylene for breast cancer imaging. "
12/01/1992 - "Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice."
08/01/1990 - "The antitumor activity of the new triphenylethylene drug toremifene has been studied in advanced breast cancer of postmenopausal women as first line treatment at dose levels of 20, 60, and 240 mg, and as second line or later treatment at high dose levels of 200-240 mg. The response rates (complete + partial response) have been 21% with 20 mg (14 patients), 52% with 60 mg (93 patients in three separate trials), and 68% with 240 mg (38 patients) as first line treatment. "
01/01/1997 - "Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-is effective in the treatment of postmenopausal breast cancer patients. "

01/01/1994 - "These compounds are able to antagonize the oestrogenic effects of triphenylethylene antioestrogens and especially the growth of resistant mammary tumors stimulated by the latter compounds. "
01/01/1994 - "It is now widely accepted that the oestrogen receptor is the major if not the only mediator of antioestrogenic and antitumoral effects of triphenylethylene antioestrogens in mammary tumor cells. "
01/01/2021 - "A series of triphenylethylene-naphthalimide (TPE-naph) conjugates was synthesized by a molecular hybridization technique, and their anticancer activity was evaluated in vitro on 60 human cancer cell lines through their cytotoxicity. "
01/01/2019 - "Selective estrogen receptor modulator drug molecules of triphenylethylene family have gained considerable attention as anti-cancer agents. "
01/01/1959 - "[Distribution of radioactivity in mammary, adipose & tumor tissues in the mouse following injection of a synthetic estrogen: radiocarbon-labeled triphenylethylene]."

01/01/2018 - "In clinical trial studies, adjuvant therapy with tamoxifen, a triphenylethylene class of SERM, has been found to reduce the frequency of manic episodes in patients with bipolar disorder, whereas addition of raloxifene, a benzothiophene class of SERM, to regular doses of antipsychotic drugs has been found to reduce cognitive deficit and psychological symptoms in men and women with schizophrenia, including women with treatment refractory psychosis. "

01/01/2018 - "In clinical trial studies, adjuvant therapy with tamoxifen, a triphenylethylene class of SERM, has been found to reduce the frequency of manic episodes in patients with bipolar disorder, whereas addition of raloxifene, a benzothiophene class of SERM, to regular doses of antipsychotic drugs has been found to reduce cognitive deficit and psychological symptoms in men and women with schizophrenia, including women with treatment refractory psychosis. "

01/01/1995 - "Recent studies have suggested that the triphenylethylene antiestrogen tamoxifen inhibits the proliferation in vitro of a substantial percentage of cell lines derived from adult high-grade gliomas, potentially acting through inhibition of the second messenger protein kinase C. "